102P A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Bibliographic record
Abstract
Background: Blood vascular angiosarcoma is an uncommon and aggressive malignancy that has responded well to several combinations of immunotherapy.Conventional medicines like radiation and chemotherapy are not very successful, however immunotherapies such bempegaldesleukin + nivolumab, epacadostat + pembrolizumab, and Immune checkpoint inhibitors (ICIs) have shown positive outcomes in certain individuals.Ipilimumab + nivolumab and pembrolizumab, have also demonstrated promise in slowing the course of the illness and raising survival rates.Methods: This study was conducted based on PRISMA reporting guidelines.All included studies were derived from PubMed, Sciencedirect, NEJM, and Europe PMC databases using a set of keywords: Angiosarcoma, Pembrolizumab, and Immunotherapies.Studies were extracted and evaluated based on inclusion (Accessible full text, Randomized Controlled Trial, Clinical Trials, and last 5 years) and exclusion criterias (non-english text, animal studies, case report, systematic reviews, and meta analysis) The quality of included studies were further assessed using Newcastle-Ottawa Scale (NOS).Results: Seven studies consisting of RCTs and clinical trials were included, screening a total of 195 patients.Among the seven studies, bempegaldesleukin + nivolumab yields 0.60 (95% Cl; 0.08-4.40;P < 0.00001), epacadostat + pembrolizumab yields 0.03 (95% Cl; 0.00-0.29;P < 0.00001), ipilimumab + nivolumab yields 0.33 (95% Cl; 0.07-1.49;P < 0.00001), pembrolizumab alone yields 3.33 (95% Cl; 0.36-30.70;P < 0.00001), and Immune checkpoint inhibitors (ICIs) yields 0.13 (95% Cl; 0.02-0.71;P < 0.00001) Adverse effect wise is 17.00 (95% Cl; 0.74-391.68;P < 0.00001), 0.30 (95% Cl; 0.10-0.92;P < 0.00001), 3.00 (95% Cl; 0.67-13.40;P < 0.00001), 0.09 (95% Cl; 0.00-2.07;P < 0.00001), and 5.00 (95% Cl; 1.07-23.46;P < 0.00001), respectively.Conclusions: This research shows that monotherapy drugs, pembrolizumab alone, are better than other combinations and ICIs in terms of ORR and adverse effect.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".